Kraków, Poland

Meet the team

We design proteins, make them in the lab and measure their interactions.

International experience in protein engineering and drug discovery

Our team brings experience from research institutes and pharmaceutical R&D. Together, we’ve contributed to 10 drug candidates that advanced to clinical development.

  • AstraZeneca
  • The Francis Crick Institute
  • MRC Laboratory of Molecular Biology
  • University of Oxford
  • Max Planck
Michał Biśta, PhD

Michał Biśta, PhD

Co-founder & CEO

Former Vice President of Structure, Fragments and Biophysics at Captor Therapeutics. Worked in drug discovery at AstraZeneca and in protein research at the MRC Laboratory of Molecular Biology and the Max Planck Institute of Biochemistry.

At AstraZeneca, contributed to the discovery of saruparib (AZD5305), a small-molecule PARP1 inhibitor being evaluated in multiple Phase 3 trials.

Strategy and drug discovery experience

Mark McAlister

Mark McAlister

Co-founder | Business Development & Protein Engineering

More than 20 years in pharma and biotech. Former Director of Biophysics at AstraZeneca and co-founder of Domainex. Led the AstraZeneca–MRC LMB Blue Skies collaboration and previously studied protein structure at the University of Oxford.

The Blue Skies collaboration he led supported more than 40 research projects and helped launch two spinouts.

Drug discovery and business development

Marta Gross, PhD

Marta Gross, PhD

Principal Founding Scientist

Protein scientist with previous research at the Francis Crick Institute and the University of Gdańsk. Former EMBO and Marie Skłodowska-Curie fellow, with experience in protein production, engineering, biochemical assay development and SPR/MST interaction measurements.

At the Crick, used cryo-electron microscopy to study how DNA replication begins.

Protein science and biology leader